Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) is.

Slides:

Advertisements

Similar presentations

Preventing Strokes One at a Time Acute Interventions and Management 2009.

Advertisements

JNC 8 Guidelines….

The British Approach to Antihypertensive Therapy: Guidelines from the National Institute of Health and Clinical Excellence Power Over Pressure

Hypertension Diagnosis and Treatment  Based on JNC 7 – published in 2003  Goal: BP

Canadian Diabetes Association Clinical Practice Guidelines Treatment of Hypertension Chapter 25 Richard E. Gilbert, Doreen Rabi, Pierre LaRochelle, Lawrence.

Pharmacological Treatment of Hypertension Update 2012.

Assessment, Targets, Thresholds and Treatment Bryan Williams NICE clinical guideline 127.

DION GALLANT, MD PRIMARY CARE SERVICE LINE MEDICAL DIRECTOR PRESBYTERIAN MEDICAL GROUP JNC 8.

Hypertension NICE CG127 August Hypertension is not a disease it is a risk factor for cardiovasuclar disease (CVD)-it is a modifiable risk factor.

Thiazide-Like/Calcium Channel Blocker (CCB) Agents: A Major Combination for Hypertension Management Safar M, Blacher J. Am J Cardiovasc Drugs. 2014; DOI.

Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.

Objective: To asses the efficacy of hydrochlorothiazide on 24-h blood pressure (BP) control.Methods: Review of all the randomized trials that assessed.

JNC 7 血壓分期. 血壓分期 JNC 7 ： 1. 增加高血壓前期 2.Stages 2 及 3 高血壓被合併 JNC 7, 2003.

Dr.AZDAKI (cardiologist).   Initial monotherapy is successful in many patients with mild primary hypertension (formerly called "essential" hypertension).

Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Renoprotective Effect of Renin-Angiotensin-Aldosterone.

April 22, 2016 Connie Tien Daniel Kim Jeffrey Hughes Michelle Di Fiore

Internal Medicine Workshop Series Laos September /October 2009.

Management of progression of CKD 순천향 대학병원 신장내과 강혜란.

Copyright © 2015 by the American Osteopathic Association.

JNC VIII Hypertension.

Hypertension JNC VIII Guidelines.

Copyright © 2015 American Medical Association. All rights reserved.

Copyright © 2005 American Medical Association. All rights reserved.

Hypertension treatment guidelines from the United Kingdom’s National Institute for Health and Care Excellence. Guidelines identify angiotensin-converting.

Vanguard Phase Results for the Blood Pressure Component

Hypertensive Guidelines

Subclinical organ damage Treatment LVH

Isolated Systolic Hypertension: An Update After SPRINT

UNIT 2: ANTIHYPERTENSIVE DRUGS

Mean BP from initial visit to four years

Sumeska Thavarajah, MD, Daphne H. Knicely, MD, Michael J. Choi, MD

Improving Transitions in CKD: Failure Mode

Nat. Rev. Nephrol. doi: /nrneph

Thinking Beyond New Clinical Guidelines: Update in Hypertension

Drug Rate ratio 95% CI Thiazide diuretics 1.0 Reference ACE inhibitors

Step Care Therapy for Hypertension in Diabetic Patients

Antihyperglycemic therapy in type 2 diabetes: general recommendations

Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or ARB is suggested to treat hypertension.

Recognition, Pathogenesis, and Treatment of Different Stages of Nephropathy in Patients With Type 2 Diabetes Mellitus George L. Bakris, MD Mayo Clinic.

Nat. Rev. Cardiol. doi: /nrcardio

Table of Contents Why Do We Treat Hypertension? Recommendation 5

Primary Hypertension Max C. Reif, M.D.

Volume 72, Issue 12, Pages (December 2007)

by Ali Albasri, Suman Prinjha, Richard J McManus, and James P Sheppard

by Ali Albasri, Suman Prinjha, Richard J McManus, and James P Sheppard

Managing Blood Pressure

Pharmacological Treatment of Hypertension Update 2012

Volume 67, Pages S52-S54 (January 2005)

Isolated Systolic Hypertension: An Update After SPRINT

Kaplan-Meier Curves for the Percentages of Subjects with Microalbuminuria during Treatment with Trandolapril plus Verapamil or Placebo Piero Ruggenenti.

Internal Medicine Workshop Series Laos September /October 2009

Volume 73, Issue 5, Pages (March 2008)

KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline

The rates of occurrences of cardiovascular, cerebrovascular, and all events expressed in cases per 1, 000 patient-years in diabetic subgroups divided by.

Percentage of patients with type 2 diabetes with A1C < 7% (n = 248), blood pressure > 130/80 mmHg (n = 248), and LDL cholesterol < 100 mg/dl (n = 207)

Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)

Two-year changes in albumin-to-creatinine ratio across microalbuminuria at baseline. Two-year changes in albumin-to-creatinine ratio across microalbuminuria.

(A) Distribution of CsA nephrotoxicity lesions according to antihypertensive treatment and CsA C2 levels. (A) Distribution of CsA nephrotoxicity lesions.

Unadjusted odds ratio of death at 6 mo for medications (β blockers [BBL], angiotensin-converting enzyme inhibitors [ACEI]/angiotensin receptor blockers.

Combination angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB) reduced risk for renal end point versus ACEI or ARB. Effect.

An updated general approach for achieving BP goals in people with diabetes. An updated general approach for achieving BP goals in people with diabetes.

(D) Systolic blood pressure (BP) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. . (D) Systolic blood pressure.

Adjusted hazard ratio (AHR) of final AVF failure by percent consistent facility aspirin use. Adjusted hazard ratio (AHR) of final AVF failure by percent.

Percentage of patients found with a kidney function too low for recommended use of the drug using estimated glomerular filtration rate compared with creatinine.

Patient disposition and study protocol.

Pathway to initial antihypertensive therapy in patients with diabetes

Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or ARB is suggested to treat hypertension.

Sumeska Thavarajah, MD, Daphne H. Knicely, MD, Michael J. Choi, MD

Fig. 3: Possible algorithm for controlling blood pressure in diabetic patients with microalbuminuria. [This algorithm is based on the opinions and practice.

Kaplan-Meier curve of the primary outcome in patients prescribed ACE inhibitor (ACEI) and angiotensin receptor blocker (ARB). Kaplan-Meier curve of the.

Presentation transcript:

Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) is suggested to treat hypertension for patients with urine albumin-to-creatinine ratio 30–299 mg/g creatinine and strongly recommended for patients with urine albumin-to-creatinine ratio ≥300 mg/g creatinine. **Thiazide-like diuretic; long-acting agents shown to reduce cardiovascular events, such as chlorthalidone and indapamide, are preferred. ***Dihydropyridine calcium channel blocker (CCB). Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) is suggested to treat hypertension for patients with urine albumin-to-creatinine ratio 30–299 mg/g creatinine and strongly recommended for patients with urine albumin-to-creatinine ratio ≥300 mg/g creatinine. **Thiazide-like diuretic; long-acting agents shown to reduce cardiovascular events, such as chlorthalidone and indapamide, are preferred. ***Dihydropyridine calcium channel blocker (CCB). BP, blood pressure. Adapted from de Boer et al. (17). American Diabetes Association Dia Care 2019;42:S103-S123 ©2019 by American Diabetes Association